Literature DB >> 3098553

Response of multiple seizure types to corpus callosum section.

J R Gates, W E Rosenfeld, R E Maxwell, R E Lyons.   

Abstract

Twenty-four patients (16 men, 8 women) underwent corpus callosum section specifically for improvement of control of atonic or tonic seizures that resulted in falls and injuries. All patients suffered from multiple seizure types, including complex partial (CP) and tonic-clonic (TC) seizures, in addition to the tonic or atonic episodes. Preoperative seizure frequency was quantified for all types for 1 year immediately before surgery and for the most recent year since the procedure; average monthly counts were obtained for each seizure type. The period of follow-up since surgery averaged 43 months (range, 23-79 months). Statistically significant improvements were documented, not only for the atonic/tonic seizures (p less than 0.0001) for all patients, but also for TC seizures (17 patients; p less than 0.001) and CP seizures (20 patients; p less than 0.02). Six patients experienced an exacerbation of CP seizures postoperatively, and three developed new simple partial (SP) seizures. In all of the CP group and all three of the SP group, ictal video and EEG features suggested that the new seizures were an aborted expression of the previously generalized seizures. From these data, we conclude that callosotomy is an effective treatment for tonic, atonic, and TC seizures intractable to anticonvulsant medications. Three patients became seizure free. The procedure may also be useful for certain specific subgroups of CP epilepsy, but further studies are required before expanding callosotomy to intractable CP seizures not amenable to focal resection.

Entities:  

Mesh:

Year:  1987        PMID: 3098553     DOI: 10.1111/j.1528-1157.1987.tb03618.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

1.  Eyebrow incision with supraorbital trephination for endoscopic corpus callosotomy: a feasibility study.

Authors:  R Shane Tubbs; Matthew D Smyth; George Salter; Kyle Doughty; Jeffrey P Blount
Journal:  Childs Nerv Syst       Date:  2004-01-23       Impact factor: 1.475

2.  Direct evidence of inter-hemispheric modulation by callosal fibers: a cortical spreading depression study in well-nourished and early-malnourished adult rats.

Authors:  Ana Virgínia Oliveira Pinto; Rubem Carlos Araújo Guedes
Journal:  Exp Brain Res       Date:  2007-11-08       Impact factor: 1.972

Review 3.  Rates and predictors of seizure outcome after corpus callosotomy for drug-resistant epilepsy: a meta-analysis.

Authors:  Alvin Y Chan; John D Rolston; Brian Lee; Sumeet Vadera; Dario J Englot
Journal:  J Neurosurg       Date:  2018-05-01       Impact factor: 5.115

4.  Epileptic drop attacks in partial epilepsy: clinical features, evolution, and prognosis.

Authors:  P Tinuper; A Cerullo; C Marini; P Avoni; A Rosati; R Riva; A Baruzzi; E Lugaresi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

5.  Neuropsychological changes after callosotomy in drug-resistant epilepsy: a study of the short-term evolution.

Authors:  L Provinciali; A Quattrini; I Papo; M Del Pesce; S Mancini
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

6.  Callosotomy for the management of intractable non-focal epilepsy: a preliminary personal assessment.

Authors:  I Papo; A Quattrini; L Provinciali; F Rychlicki; A Paggi; M Del Pesce; A Ortenzi
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

7.  Callosotomy for severe epilepsies with generalized seizures: outcome and prognostic factors.

Authors:  G F Rossi; G Colicchio; E Marchese; A Pompucci
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Anterior corpus callosotomy in patients with drug-resistant epilepsy: Invasive EEG findings and seizure outcomes.

Authors:  Olga Taraschenko; Swetha Pedavally; Kaeli K Samson; Mark J Puccioni; Deepak Madhavan
Journal:  Epilepsy Behav Case Rep       Date:  2017-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.